Pillar Biosciences' oncoReveal Essential+ assay has been validated at LSI Medience Corporation for screening cell-free DNA and cell-free RNA from lung cancer patients enrolled in LC-SCRUM-Asia, the Japanese genomic screening network led by the National Cancer Center Hospital East. Testing is planned to begin in August 2026 and the project is expected to cover about 2,000 patients over two years. LSI Medience will perform the testing.
- Announced: August 19, 2026, from Natick, Massachusetts and Tokyo.
- Scale: approximately 2,000 patients over a two-year period.
- Trigger: a revision to the LC-SCRUM-Asia project protocol was approved before testing could start.
- Analytes: cfDNA and cfRNA from blood specimens, run on Pillar's oncoReveal Essential+ targeted NGS panel.
- Testing site: LSI Medience, a Japanese subsidiary of PHC Holdings Corporation established in 1975.
A Protocol Revision Cleared the Way
The three parties said testing follows approval of a revision to the LC-SCRUM-Asia project protocol, with the participating organizations planning to begin in August 2026. That timing places the first specimens inside the same month the collaboration was announced. LC-SCRUM-Asia is described as a large-scale lung cancer genomic screening and clinical research network led by the National Cancer Center Hospital East, drawing in medical institutions, diagnostic laboratories and pharmaceutical companies to find genomic alterations and route patients toward biomarker-driven therapy.
Fusions Sit on the RNA Side
The validation at LSI Medience covers both cell-free DNA and cell-free RNA. Fusion detection in lung cancer sits mainly on the RNA side, and running both analytes through a single targeted panel keeps a fusion-positive case from needing a second workflow. Pillar said the deployment reflects the assay's ability to support targeted sequencing from blood-based specimens within a decentralized laboratory workflow, which is the company's standing argument for kitted panels run at the testing site instead of a central reference laboratory.
What Goto and Harma Said
"The use of oncoReveal Essential+ through LSI Medience will provide the LC-SCRUM-Asia network with a highly accurate and accessible liquid biopsy solution for analyzing cfDNA and cfRNA from patients with non-small cell lung cancer, while supporting the rapid turnaround needed for clinical research," said Dr. Koichi Goto of LC-SCRUM-Asia. Daniel Harma, chief commercial officer at Pillar Biosciences, said the company was pleased the assay had been validated at LSI Medience for both analytes and looked forward to supporting the project.
Regulatory Standing Is Not Stated
The announcement describes a site validation at a clinical laboratory, and it gives no regulatory classification for the Essential+ configuration in Japan. Pillar's public catalog lists its oncoReveal liquid biopsy panels, including an Essential LBx panel, as research use only, while the company's broader portfolio spans both in vitro diagnostic and research-use products. Neither the panel's gene content nor its limit of detection appears in the release.
Why This Matters to the APO|APE Reader
An enrollment window that opens in August 2026 and runs two years puts the last specimens somewhere around mid-2028, which is the horizon for any evidence this generates about decentralized blood-based screening at national scale. No financial terms were disclosed and no pharmaceutical sponsor of the screening itself was named, so the commercial shape of the arrangement stays unclear even though drug companies are listed among the network's partners. For laboratories weighing kitted panels against send-out liquid biopsy, a 2,000-patient prospective cohort run at a single Japanese testing site is a rare chance to see failure rates and turnaround measured in a real screening program rather than a validation study.
